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Objectives: to evaluate the long-term results of stenting in iliac and aortic occlusive disease and identify factors predicting
clinical outcome.
Design: retrospective study.
Materials and Methods: 82 patients (87 limbs) with stenoses (n=63) and occlusions (n=24) in the aortoiliac segment
were treated with stents. 81 lesions involved the iliac arteries, 3 the infrarenal aorta and 3 the aortic bifurcation. Primary
stenting was performed in 57 limbs (complex stenotic lesions and occlusions). Stents were placed following failed PTA
in 30 limbs. Median follow-up was 13.2 months (1–66 months).
Results: technical success was 99% and clinical success 89%. Cumulative primary and secondary patency of stented
iliac atherosclerotic lesions at 1 and 3 years was 75 and 61%, and 83 and 75% respectively. The factors predicting
outcome of primary patency identified in Cox multivariate analysis were ankle–brachial index (ABI) prior stenting (p=
0.03) and length of the lesion (p=0.007). Major non-fatal complications occurred in 7.4% of the patients and there were
no deaths attributed to the treatment. The 30-day mortality was 3.7%.
Conclusion: stenting of complex aortoiliac stenoses and chronic occlusions is a safe and effective treatment modality.
Long lesions and lower pre-procedure ABIs were found to negatively influence outcome.
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Introduction Material and Methods
Percutaneous transluminal angioplasty (PTA) is the Between October 1990 and December 1994, 87 limbs
treatment of choice for patients with symptomatic in 82 patients were treated by the percutaneous place-
concentric non-calcified short stenoses of the aortoiliac ment of endovascular metal stents for symptomatic
arterial segment.1 Resistance to dilatation, elastic recoil, occlusive disease of the aortic and iliac segment. All
flow-limiting dissection, thrombosis or spasm may patients’ medical charts including interventional treat-
result in failed PTA. Late restenosis may be due to ment records were reviewed. It was not possible retro-
intimal hyperplasia, progressive disease or arterial spectively to analyse the material on an intention-to-
remodelling.2 During the last decade, the percutaneous treat. Demographic data are presented in Table 1.
placement of metallic stents has been established as a Using the Fontaine classification,12 two patients had
complementary procedure in the setting of an un- stage IIa disease (intermittent claudication with a walk-
satisfactory PTA.3–10 Stent placement has also been ing distance >200 m), 52 had stage IIb disease (walking
used in the treatment of chronic arterial occlusions distance <200 m), 14 had stage III disease (rest pain)
and complex lesions, i.e. long, multiple, eccentric and/ and 14 had stage IV disease (tissue loss). One patient
or calcified stenoses.11 The aim of this retrospective with stage IV disease was treated because of micro-
study was to evaluate our long-term results of stent embolism, i.e. ‘‘blue toe syndrome’’.
treatment in aortoiliac occlusive disease. Additionally, There were 63 stenoses and 24 occlusions. The aeti-
predictive factors influencing clinical outcome of the ology of the lesions were atherosclerosis in 74 patients,
procedure were identified. restenosis after previous PTA in six, anastomotic sten-
osis of an aortobi-iliacal graft in one, and one patient
* Please address all correspondence to: P. Uher, Department of was considered to have Takayasu arteritis. The char-Radiology, Malmo¨ University Hospital, University of Lund, S-205
02 Malmo¨, Sweden. acteristics of the lesions are presented in Table 2. Three
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Table 1. Demographic data. Strecker stents (Medi-tech/Boston Scientific, Water-
town, MA, U.S.A.) in 7 and an experimental balloon-Parameter No. of (%)
patients expandable spiral tantalum stent (Meadox, Cad-
dington, England) in 7 limbs. Combinations of Palmaz
Mean age (range) 65.5 (40–86) years and Wallstents were placed in two limbs, Strecker andSex
Female 43 (52) Wallstents in one limb and Palmaz, Wallstent and
Male 39 (48) Meadox Surgimed stents in one limb. Characteristics
Indication of the stents and deployment techniques have been
Claudication 54 (66) previously described.3,4,6 Occluded vessels were gen-Pain at rest 14 (17)
erally not dilated prior to stent placement; however,Ischaemic ulcer 10 (12)
Gangrene 4 (5) heavily calcified occluded vessels were predilated with
an undersized balloon (4 mm). Thrombolytic therapyRisk factors
Smoking 56 (68) was utilised prior to stenting in one patient with an
Hypertension 48 (59) aortic occlusion. The total number of stents placed wasIschaemic heart disease 31 (38)
Diabetes 22 (27) 129 with an average 1.5 stent per limb. Periprocedural
Impaired renal function 8 (10) anticoagulation was obtained using an intra-arterial
Previous aortoiliac PTA or surgery 11 (13) administration of heparin (50–100 IU/kg body weight)
which was supplemented during extended proceduresMean pre-stent ABI (range) 0.51 (0.00–1.13)
by the administration of 10–20 IU/kg boluses heparin
each hour. Arteriography of the distal vessels was not
performed routinely post-stenting due to concernspatients had lesions involving the aortic bifurcation
regarding the amount of contrast medium used, pres-and origin of both common iliac arteries (CIA). Two
ence of impaired renal function and/or diabetes mel-patients had isolated aortic occlusions and one a sten-
litus.osis.
Additional interventions were performed in 19A lesion was considered haemodynamically sig-
patients. These included femorofemoral cross-overnificant if (1) the lumen diameter reduction was[75%
grafting (n=6), thromboendarterectomy of the deep orcompared to an adjacent normal vessel segment,13
common femoral artery (n=4), femoropopliteal bypass(2) the trans-stenotic mean arterial blood pressure
(n=3), PTA of the superficial (n=2) and deep femoralgradient at rest was [10 mmHg or (3) there was a
artery (n=1), ilioprofundal bypass with an exclusion[15% decrease in systolic pressure index (arterial
of a post-surgical pseudoaneurysm of the deep femoralpressure distal to the lesion/arterial pressure proximal
artery (n=1), endoluminal stent-graft placement dueto the lesion) after injection of 30 mg papaverine distal
to a subtotal occlusion of the external iliac and commonto the stenosis14 in claudicants with a <10 mmHg mean
femoral artery (n=1), and percutaneous aspiration ofgradient at rest.
peripheral emboli present prior to stent placement andPrimary stenting was performed in 24 occlusions,
originating from a stenotic iliac artery (n=1). These27 eccentric and/or heavily calcified stenoses and 6
interventions were performed at the same setting asrestenoses after previous PTA. Secondary stenting,
stent placement in 5 patients (PTA of superficial fem-following a failed PTA, i.e. a persisting significant
oral artery (n=3), thromboendarterectomy of deeptrans-stenotic pressure gradient, markedly decreased
femoral artery (n=1) and aspiration of peripheralblood flow and/or a poor anatomical result (residual
emboli (n=1)) and at different occasions in 14 patients.stenosis [50%), was performed due to dissection in
In 13 patients the outflow procedure was planned,21 and elastic recoil in nine arteries.
and in the remaining 6 patients it was performed whenWallstents (Schneider, Bu¨lach, Switzerland) were
it was evident that the stent implantation alone wasplaced in 47 limbs, Palmaz stents (Johnson & Johnson
Interventional Systems, Warren, NJ, U.S.A.) in 22, not enough to relieve the symptoms.
Table 2. Lesions’ characteristics.
Site of lesion Occlusions Stenoses Length (cm) Length (cm)
(No.) (No.) (range) (mean)
Common iliac 13 23 0.5–6 2.9
External iliac 8 28 0.3–15 3.3
Common and external iliac 1 11 1.0–13.8 4.1
Aorta (isolated lesions) 2 1 2.3–3 2.7
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Technical success was defined as smooth apposition our experience resulted in an obstructive dissection
of the stent to the vessel wall judged from ar- extending into the CIA. Subsequent stent treatment
teriography with a residual lumen diameter reduction failed because it did not cover the entire dissection. The
of Z30% and a mean trans-stent pressure gradient patient required aortobifemoral grafting two months
<10 mmHg. Antiplatelet therapy was initiated after later. Stents were incorrectly deployed in two limbs,
stent deployment with the daily administration of but endovascular salvage was accomplished with ad-
75–160 mg acetylsalicylic acid. Patients with ex- ditional stenting. Periprocedural thrombosis of stents
ceptionally poor peripheral run-off were given post- occurred in three limbs. The acute events were at-
procedural heparinisation for period of 1–3 days. tributed to insufficient heparinisation in one patient,
Clinical success was defined as an improvement in a possible hypercoagulable state in a patient with
at least one category in stage 2 and 3 disease and an ovarian carcinoma, and in one patient following
by two categories in stage 4 disease in the Fontaine recanalisation of an occluded distal aorta and bi-
classification system and the improvement of the furcation. All occlusions were successfully treated with
ankle–brachial index (ABI) by more than 0.1.15 the local administration of thrombolytic agents. Thus,
Patient follow-up included clinical assessment of the final technical success was 99%; 86 of 87 limbs,
symptoms, palpation of femoral and distal pulses, with a 95% confidence interval (CI) of 94 to 100%.
Doppler ABI measurements (73 limbs), arteriography Clinical success was obtained in 73 of 82 patients
(36 limbs) and duplex ultrasound (8 limbs) over a (77 of 87 limbs; 89% CI 80–94%). In 10 of the 77 limbs
median period of 13.2 months (range 1–66 months). ABI measurements were missing. Clinical failures in-
Indications for arteriography were symptom re- cluded one technical failure mentioned above and
currence (n=17), scheduled follow-up (n=12), per- two patients without improvement of their symptoms
sistent symptoms (n=3) and contralateral symptoms despite an increase of ABI in one and angiographically
(n=4). proved patency of the stent in the other. Their symp-
Criteria according to Rutherford et al. were used toms were regarded as non-ischaemic. Another six
to define patency of the stented vascular segment.15 patients (7 limbs) did not improve after stent place-
Recurrence of symptoms on routine clinical follow- ment; five of them due to poor run-off, i.e. ar-
up prompted radiologic re-evaluation. Patients with teriographic occlusion of at least one femoral artery
either arteriographic evidence of restenosis ([50% and all infrapopliteal arteries. Three of these patients
diameter reduction9,16 or a trans-stenotic pressure required a below-the-knee amputation and the other
gradient which was successfully treated with two died; one, seven days after the stent placement
supplemental interventions constituted an assisted due to progressive bilateral foot and lower leg gan-primary patency group. Reoccluded limbs sucessfully
grene, and one after 42 days due to multi-organ failure.revascuralised with endovascular techniques defined
In the sixth patient a femorofemoral cross-over graftthe secondary patency group. The Kaplan–Meier
following the stent procedure resulted in occlusion ofmethod was used to determine the cumulative patency
an old femoropopliteal graft, severe ischaemia, myo-rates of the limbs with iliac atherosclerotic lesions.16
cardial infarction and the patient’s death.The relationship between primary patency and the
There were three early (Z30 days) clinical failures.following risk factors was evaluated: ischaemic heart
Two patients presented with thrombosis of primarilydisease, diabetes mellitus, current smoking, symptom
stented occlusion, one of the CIA and one of the EIA.severity, ABI, patency of superficial femoral artery
Intra-arterial thrombolysis failed in both cases. An(SFA), lesion type, lesion site and length. Variables
incompletely treated EIA and CIA dissection resultedwere tested using a univariate analysis comparing two
in the third clinical failure. All three patients weresurvival curves with the Peto-Peto–Wilcoxon test. The
treated with a femorofemoral bypass graft.Cox proportional hazard multivariate analysis was
There were 12 late failures (eight restenoses andused to evaluate the prognostic value of the risk factors
four occlusions), which occurred at a median time ofwith p<0.20 (Tables 4 and 5). The StatView˛ software
10.3 months (range 1.4–26.1) after initial stent place-(Abacus Concepts, Inc., CA, U.S.A.) was used for the
ment. The restenoses, all within the stented part of thestatistical analysis.
vessel, were treated with PTA in six cases and with
additional stent placement in two. One occlusion was
treated with thrombolysis followed by PTA of anResults
underlying restenosis within the stent, one with throm-
bolysis and additional stent placement because ofStent placement was primarily successful in 81 of 87
limbs. PTA of an external iliac artery (EIA) early in progression of proximal atherosclerotic disease, and
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Table 3. Life-table analysis of patency (atherosclerotic iliac lesions).
Patency Cumulative patency Limbs at risk s.e.
(months) (%) (No. 77) (%)
Primary
3 86.0 56 4.1
6 82.6 48 4.6
9 82.6 44 4.6
12 74.7 36 5.6
18 67.7 16 6.9
24 67.7 12 6.9
30 60.9 5 9.0
36 60.9 4 9.0
Assisted primary
12 81.4 40 4.9
24 81.4 14 4.9
36 67.2 5 10.5
Secondary
12 83.3 41 4.6
24 83.3 14 4.6
36 75.0 5 9.0
Table 4. Risk factors evaluated in univariate analysis.
No. of limbs Failure p
ABI** 69 18 0.03*
(continuous, 0.1)
ABI** 0.05
<0.50 32 10
[0.50 37 8
Length of the lesion 0.007
>3 cm 23 10
Z3 cm 54 9
Patency of SFA** 0.37
Occluded 24 6
Patent 45 11
Symptoms 0.19
Critical ischaemia 25 7
Intermittent claudication 52 12
Type of the lesion 0.41
Occlusion 22 6
Stenosis 54 12
Site of the lesion 0.95
EIA, both EIA and CIA 45 11
CIA 32 8
Type of the stent** 0.66
Palmaz 20 3
Wallstent 43 10
Diabetes** 0.50
Yes 18 3
No 58 16
Current smoking** 0.54
Yes 52 15
No 15 2
Ischaemic heart disease** 0.69
Yes 28 7
No 48 12
p values obtained by the generalised Peto-Peto–Wilcoxon test comparing two survival
curves.
* p value obtained by the proportional hazard analysis.
** Presence of the risk factor not available in all patients.
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Table 5. Factors evaluated in Cox proportional hazard multivariate analysis.
Variable Groups* s.e. Relative hazard p
(95% CI)
Age Continuous, 10 yr 0.23 1.1 (0.7–1.8) 0.58
ABI Continuous, 0.1 0.10 1.2 (1.0–1.5) 0.02
Length of the lesion >3 cm vs. Z3 cm 0.54 5.0 (1.8–14.1) 0.002
Symptoms’ severity Critical ischaemia vs. claudication 0.57 1.0 (0.3–3.0) 0.98
* 69 limbs available for the multivariate analysis.
three-year primary and secondary patency rates for
the whole group were 67 and 82%. The pretreatment
ABI and the lesion length were the only factors that
were found to be independently predictive of primary
patency outcome in iliac atherosclerotic lesions (Tables
4 and 5). The cumulative one-year primary patency
rates for limbs with ABI <0.50 (median value) was
63%, compared with 83% in limbs with ABI [0.50
(p=0.05). In limbs with lesions longer than 3 cm the
cumulative one-year patency rate was 50% compared
with 84% in limbs with lesions 3 cm long or shorter
(p=0.007, Peto-Peto–Wilcoxon test, Table 4).
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Fig. 1. Patency according to Kaplan–Meier analysis. (––) Primary
patency; (–·–·) assisted primary patency; (· · · · ·) assisted primary Six major periprocedural complications occurred with-patency (s.e. >10%); (–––) secondary patency.
out any fatalities (7.3%, 95% CI 3–15%). There were
three groin haematomas requiring surgical therapyone occlusion was left untreated. One patient died of
(n=2) or transfusion (n=1). One patient suffered aheart failure three days after the occlusion had been
myocardial infarction. Two diabetic patients (one withdiagnosed. Reocclusion occurred in three of the 10
a renal transplant) developed persistent renal failure,treated limbs at 14, 15 and 30 months following the
but neither required dialysis (increase of serum cre-second endovascular reintervention. One patient was
atinine from 136 to 300 lmol/l and 130 to 400 lmol/ltreated with second PTA, one with an ipsilateral ili-
respectively).ofemoral bypass graft, and one patient was left un-
Minor complications were noted in five patientstreated. In summary, recurrent disease within the
(6.1%, 95% CI 2–14%). These included four groin haem-treated vascular segment occurred in 15 of the 73
atomas and a single asymptomatic embolus to a branchinitially successfully treated patients requiring 13 per-
of the deep femoral artery. None required therapy,cutaneous and four surgical reinterventions. Fourteen
and hospital stay was not prolonged in this group ofof these recurrent lesions were in patients treated for
patients.iliac atherosclerotic disease and one in a patient treated
The 30-day mortality rate was 3.7% (95% CI 1–10%).for restenosis after previous PTA.
Deaths resulted from myocardial infarction (n=2) fol-Five patients required below-the-knee amputations
lowing surgical reconstruction and progressive bi-(5.6%, 95% CI 2–13%) at a median time of 2 months
lateral lower extremity gangrene (n=1).(range 0.2–6 months). Three amputations occurred
among the initial clinical failures described above. In
the remaining two patients the stented artery was
patent and the amputation was performed due to Discussion
distal progression of atherosclerotic disease.
The cumulative one- and three-year primary patency During the last 20 years PTA of aortic and iliac ath-
erosclerotic occlusive lesions has become widely ac-rates of atherosclerotic iliac arteries (n=77) were cal-
culated to be 75 and 61% respectively, and secondary cepted as an alternative to bypass grafting in selected
patients.12 However, restenosis rates of 10–40% havepatency 84 and 76% (Table 3, Fig. 1). The cumulative
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been noted.12,17 Complex lesions including heavily cal- our data demonstrated that only the preprocedural
ABI and the length of the lesion were statisticallycified stenoses, long eccentric lesions and iliac oc-
clusions respond less favourably to PTA.1 The results significant in predicting patency. The presence of a
stenosis rather than an occlusion, stent diameter, smok-of the present retrospective study demonstrate that
safe and effective treatment of complex aortoiliac le- ing and SFA disease were not helpful in predicting
sustained clinical success.sions can be accomplished with stenting. At three
years the primary, primary assisted and secondary There are few reports describing the use of stents
in isolated atherosclerotic infrarenal aortic lesions.23–25patency rates of atherosclerotic iliac artery lesions were
61, 67 and 76%, respectively. In addition, there were Primary and secondary patency rates, during a mean
follow-up period of 15 to 19 months, were 86 andno procedure-related mortalities and only 3 of 82
patients (3.7%, 95% CI 1–10%) suffered any com- 100% respectively. Two of the authors reported no
major complications, while one23 had 21 per cent in-plication with permanent sequelae.
Our patency rates were somewhat lower than re- cidence of major complications. The suggested in-
dications for stent placement in isolated aortic lesionsported by others. In a large multicentre iliac stent trial
Palmaz et al.8 demonstrated a clinical and ar- have been: unsuccessful PTA, late recurrent stenosis,
chronic occlusions, intraluminal atherosclerotic debris,teriographic patency rate of 90% and 94% respectively
at 12 months. Vorwerk reported a 95% primary patency stenotic graft anastomosis, and eccentric, calcified or
irregular lesions. We stented three isolated aortic le-rate at one year and 82% at four years in the treatment
of failed PTA of iliac stenoses. Secondary patency rates sions and did not observe any complications. All three
patients had resolution of their symptoms. Althoughof 96% and 91% were noted at one and four years
respectively. Recanalisation followed by primary stent aortic PTA has been shown to be safe and effective,
primary stenting may prevent distal embolisation.placement in chronic iliac artery occlusions resulted
in primary and secondary patency rates of 78% and Aortic stents also prevent recoil which permits under-
dilatation of heavily calcified lesions, thereby de-88% at four years.10,18 The multicentre Wallstent trial
calculated the primary and secondary clinical patency creasing the risk of aortic rupture.25
Historically aortobifemoral bypass surgery has had arates to be 81% and 91% at one year and 71% and 86%
at two years.9 Strecker et al. reported primary patency higher patency rate at five years ranging from 80–95%,
compared to angioplasty and stent placement. How-rates of 85% at three years and 79% at five years.19
The majority of our technical failures and early ever, the reported early mortality (1% to 5%) and
morbidity (9% to 20%)26,27 of surgery is substantiallyocclusions occurred early in our experience. The causes
included incomplete sealing of dissections, inaccurate higher than for endovascular procedures. The most
common early surgical complications are haemorrhagestent deployment and insufficient procedural anti-
coagulation. In three patients, dissections following (1–2%), limb ischaemia (1–10%), renal failure (4–8%),
and intestinal ischaemia (1–2%). In addition, latePTA were incompletely covered; two of them required
surgical interventions and one lesion required ad- complications include anastomotic pseudoaneurysms
(1–5%), graft infection (1–2%), aortoenteric fistuladitional stenting following a recurrent stenosis 3
months after the initial procedure. We concluded that (0.4–2.4%) and neurogenic impotence (25%).28 In a
literature review of 6620 patients undergoing aortoiliacit is advisable to cover lesions completely and seal all
dissections.7 Another reason for our lower patency PTA the complication rate was 8.1%.29 Major com-
plications occurred in only 2.7%, with only 1.2% re-figures may be the inclusion of five compassionate
cases with extremely poor run-off, three of whom quiring surgery and the mortality rate was 0.2%, about
one-tenth of that reported for surgical reconstructions.underwent amputation and two died.
Late (>30 days) stent occlusions may result from The most common complications were puncture
site haematoma (2.9%), pseudoaneurysm/AV-fistulaintimal hyperplasia, vessel remodelling or progressive
atherosclerotic disease. Potentially negative prognostic (0.5%), acute arterial occlusion (1.9%), distal em-
bolisation (1.6%) and renal dysfunction (0.7%). Arterialfactors have included: incomplete covering of the le-
sion, length (>60 mm) of the stented segment, complete rupture at the site of PTA occurred in only 0.2% of
the patients. Clearly, many of the complications ofocclusion, SFA occlusion, stenting of the EIA, stent
diameter less than 8 mm, and continued smoking.19–21 angioplasty can be managed with adjunctive en-
dovascular interventional procedure including ad-Patency rates in iliac segments treated with PTA alone
have been related to the site of PTA, quality of peri- ditional stenting for acute occlusions due to dissection,
thrombolysis for acute thrombosis, aspiration of distalpheral run-off, diabetes mellitus and treatment in-
dication (claudication vs. rest pain).22 Assessment of emboli, and stent-graft treatment for arterial ruptures.30
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